This drug entry is a stub and has not been fully annotated. It is scheduled to be annotated soon.
Identification
- Summary
Ferric oxide is an ingredient used in a number of skin protecting products.
- Brand Names
- Baby Anti Monkey Butt Diaper Rash Powder, Caladryl, Calazime Skin Protectant
- Generic Name
- Ferric oxide
- DrugBank Accession Number
- DB11576
- Background
Iron(III) oxide or ferric oxide is the inorganic compound with the formula Fe2O3. It is one of the three main oxides of iron, the other two being iron(II) oxide (FeO) the rarer form, and iron(II,III) oxide (Fe3O4) which naturally as magnetite.
- Type
- Small Molecule
- Groups
- Experimental
- Structure
Structure for Ferric oxide (DB11576)
- Weight
- Average: 159.687
Monoisotopic: 159.854616 - Chemical Formula
- Fe2O3
- Synonyms
- Anhydrous Ferric Oxide
- Anhydrous Iron (III) Oxide
- Blood stone
- Eisen(III)-oxid
- Eisentrioxid
- Ferric oxide red
- Hematite
- Indian red
- Iron oxide
- Iron oxide red
- Iron oxide, red
- Iron trioxide
- Iron(III) oxide
- External IDs
- 215-168-2
- E 172 Red
Pharmacology
- Indication
Not Available
Reduce drug development failure ratesBuild, train, & validate machine-learning modelswith evidence-based and structured datasets.Build, train, & validate predictive machine-learning models with structured datasets.- Associated Conditions
Indication Type Indication Combined Product Details Approval Level Age Group Patient Characteristics Dose Form Used in combination to prevent Damaged skin Combination Product in combination with: Zinc oxide (DB09321) ••• ••• •••••• - Contraindications & Blackbox Warnings
Prevent Adverse Drug Events TodayTap into our Clinical API for life-saving information on contraindications & blackbox warnings, population restrictions, harmful risks, & more.Avoid life-threatening adverse drug events with our Clinical API- Pharmacodynamics
Not Available
- Mechanism of action
- Not Available
- Absorption
Not Available
- Volume of distribution
Not Available
- Protein binding
Not Available
- Metabolism
- Not Available
- Route of elimination
Not Available
- Half-life
Not Available
- Clearance
Not Available
- Adverse Effects
Improve decision support & research outcomesWith structured adverse effects data, including: blackbox warnings, adverse reactions, warning & precautions, & incidence rates. View sample adverse effects data in our new Data Library!Improve decision support & research outcomes with our structured adverse effects data.- Toxicity
Not Available
- Pathways
- Not Available
- Pharmacogenomic Effects/ADRs
- Not Available
Interactions
- Drug Interactions
- This information should not be interpreted without the help of a healthcare provider. If you believe you are experiencing an interaction, contact a healthcare provider immediately. The absence of an interaction does not necessarily mean no interactions exist.
Drug Interaction Integrate drug-drug
interactions in your softwareAlendronic acid Ferric oxide can cause a decrease in the absorption of Alendronic acid resulting in a reduced serum concentration and potentially a decrease in efficacy. Asenapine Asenapine can cause a decrease in the absorption of Ferric oxide resulting in a reduced serum concentration and potentially a decrease in efficacy. Calcium Phosphate Ferric oxide can cause a decrease in the absorption of Calcium Phosphate resulting in a reduced serum concentration and potentially a decrease in efficacy. Calcium phosphate dihydrate Ferric oxide can cause a decrease in the absorption of Calcium phosphate dihydrate resulting in a reduced serum concentration and potentially a decrease in efficacy. Carbidopa Ferric oxide can cause a decrease in the absorption of Carbidopa resulting in a reduced serum concentration and potentially a decrease in efficacy. - Food Interactions
- Not Available
Products
Drug product information from 10+ global regionsOur datasets provide approved product information including:dosage, form, labeller, route of administration, and marketing period.Access drug product information from over 10 global regions.- Mixture Products
Name Ingredients Dosage Route Labeller Marketing Start Marketing End Region Image Aloe Vera Calamine Ferric oxide (8 g/100mL) + Zinc oxide (8 g/100mL) Lotion Topical 1201258 Ontario Inc O/A Nanz Pharma 2023-05-05 Not applicable US 
Anti Monkey Butt Diaper Rash Ferric oxide (0.001 g/1g) + Zinc oxide (0.139 g/1g) Cream Topical Dse Healthcare Solutions, Llc. 2010-05-01 2012-04-16 US Anti Monkey Butt Diaper Rash Ferric oxide (0.001 g/1g) + Zinc oxide (0.139 g/1g) Cream Topical Dse Healthcare Solutions, Llc. 2012-04-18 2014-10-14 US Au Kah Chuen Fugical Ferric oxide (0.05 g/100g) + Diphenhydramine hydrochloride (2 g/100g) + Zinc oxide (9.95 g/100g) Cream Topical Zhejiang Dingtai Pharmaceutical Co., Ltd 2019-06-10 Not applicable US Aveeno Anti Itch Concentrated Ferric oxide (0.6 mg/1mL) + Pramoxine hydrochloride (10 mg/1mL) + Zinc oxide (29.4 mg/1mL) Lotion Topical Johnson & Johnson Consumer Inc. 2012-11-07 2023-12-01 US
Categories
- ATC Codes
- V08CB03 — Iron oxide, nanoparticles
- Drug Categories
- Chemical TaxonomyProvided by Classyfire
- Description
- This compound belongs to the class of inorganic compounds known as transition metal oxides. These are inorganic compounds containing an oxygen atom of an oxidation state of -2, in which the heaviest atom bonded to the oxygen is a transition metal.
- Kingdom
- Inorganic compounds
- Super Class
- Mixed metal/non-metal compounds
- Class
- Transition metal organides
- Sub Class
- Transition metal oxides
- Direct Parent
- Transition metal oxides
- Alternative Parents
- Inorganic salts / Inorganic oxides
- Substituents
- Inorganic oxide / Inorganic salt / Transition metal oxide
- Molecular Framework
- Not Available
- External Descriptors
- iron oxide (CHEBI:50819)
- Affected organisms
- Not Available
Chemical Identifiers
- UNII
- 1K09F3G675
- CAS number
- 1309-37-1
- InChI Key
- JEIPFZHSYJVQDO-UHFFFAOYSA-N
- InChI
- InChI=1S/2Fe.3O
- IUPAC Name
- oxo[(oxoferrio)oxy]iron
- SMILES
- O=[Fe]O[Fe]=O
References
- General References
- Not Available
- External Links
Clinical Trials
- Clinical Trials
Phase Status Purpose Conditions Count 4 Completed Diagnostic Pancreatic Cancer 1 4 Completed Treatment Melasma 1 4 Completed Treatment Periodontitis, Apical / Pulp Disease, Dental 1 2 Completed Treatment Hyperphosphataemia 1 2 Recruiting Diagnostic Breast Cancer / Sentinel Lymph Nodes 1
Pharmacoeconomics
- Manufacturers
- Not Available
- Packagers
- Not Available
- Dosage Forms
Form Route Strength Cream Topical Powder Topical Suspension Topical Aerosol, spray Topical Liquid Topical Ointment Topical Ointment Rectal; Topical Dressing Topical Lotion Cutaneous Paste Topical Lotion Topical - Prices
- Not Available
- Patents
- Not Available
Properties
- State
- Solid
- Experimental Properties
- Not Available
- Predicted Properties
Property Value Source logP 0.37 Chemaxon pKa (Strongest Basic) -3 Chemaxon Physiological Charge 0 Chemaxon Hydrogen Acceptor Count 2 Chemaxon Hydrogen Donor Count 0 Chemaxon Polar Surface Area 43.37 Å2 Chemaxon Rotatable Bond Count 2 Chemaxon Refractivity 4.24 m3·mol-1 Chemaxon Polarizability 7.03 Å3 Chemaxon Number of Rings 0 Chemaxon Bioavailability 1 Chemaxon Rule of Five Yes Chemaxon Ghose Filter No Chemaxon Veber's Rule No Chemaxon MDDR-like Rule No Chemaxon - Predicted ADMET Features
- Not Available
Spectra
- Mass Spec (NIST)
- Not Available
- Spectra
- Not Available
- Chromatographic Properties
Collision Cross Sections (CCS)
Not Available
Drug created at April 12, 2016 03:00 / Updated at September 28, 2021 21:54